The investment from Maven Capital Partners includes backing from the Investment Fund for Scotland.
"Podfather is a leading operator within its field, and we are delighted to have provided our clients with the opportunity to invest in this well established and profitable business. With our backing, and the clear ambition of Colin and his team, we are confident Podfather’s growth strategy can be realised and we look forward to helping the business capitalise on the growing market opportunity."
Maven Capital Partners led the multi-million investment to support product development and international growth.
"Kani has developed an innovative, award-winning platform that is addressing a critical challenge in the fast evolving payments industry. The company’s proprietary technology, coupled with the team’s deep sector expertise, has helped the business achieve year on year growth with annual recurring revenues sharply increasing in the last year, driven by a 70% increase in clients. With the increasing complexity of payment reconciliation and regulatory compliance, demand for Kani’s solution is set to grow further. We are excited to support Aaron and his team as they scale the business and expand into new global markets, particularly with significant opportunities emerging in the US."
Eos Advisory led the Series A round alongside new and existing backers to fund international expansion and commercialisation.
"The Dxcover technology combines deep technical innovation with machine learning to radically change the diagnostic landscape. Over the last three years they have conclusively shown the accuracy and ease of use of their diagnostic test across multiple cancer indications. This is very much aligned with Eos’ approach to investing in innovation that has the potential to impact positively in people's lives. More recently the team at Dxcover have focused on building a world class international team on both sides of the Atlantic. This funding round is very much about commercialization in both the UK and the US."
The investment round was led by Maven Capital Partners through the Investment Fund for Scotland alongside Scottish Enterprise.
"We are delighted to have secured this significant investment led by Maven, which highlights the strength of our technology and reinforces our vision for the future of water disinfection. This funding represents a tremendous opportunity to scale our operations, drive innovation through research and development, and deliver sustainable, cost-effective water treatment solutions to a growing global market."
The Edinburgh spinout will use the capital to launch new programmes and establish its operational footprint.
"We are so excited to be taking the next step in our spin-out journey and want to sincerely thank all the investors and supporters who have helped us make it happen. Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible. This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work, and we look forward to using the funding to further develop our technology."
